Latest Biotech News

Researchers at St. Jude Children’s Research Hospital published CHANGE‑seq‑BE, a resource‑efficient, unbiased method to detect genome‑wide off‑target activity of base editors. The team demonstrated...

A preclinical study demonstrated that CRISPR–Cas3, delivered by lipid nanoparticles, can generate directional, long‑range deletions at the TTR locus in mice, achieving ~48.7% hepatic editing and...

Amgen agreed to acquire Oxford University spinout Dark Blue Therapeutics for up to $840 million to add a preclinical small‑molecule degrader aimed at MLLT1/3‑driven acute myeloid leukemia (AML)....

Variant Bio and Boehringer Ingelheim struck a research collaboration and license to discover novel targets for kidney and cardiorenal disease, with Variant eligible for upfront and milestone...

Insilico Medicine signed a multiyear R&D collaboration with France’s Servier valued at as much as $888 million to apply Insilico’s AI discovery platform to oncology programs, following the...

Pfizer signed a multiyear discovery collaboration with Cartography Biosciences to identify tumor‑selective antigens, a deal that could be worth up to $865 million if all options and milestones are...

Arrowhead Pharmaceuticals reported early clinical signals from RNAi candidates targeting obesity biology, including ARO‑INHBE, which produced meaningful fat‑loss when dosed in combination with Eli...

Zenas Biopharma’s obexelimab hit the primary endpoint in the Phase III Indigo trial for immunoglobulin G4‑related disease but the magnitude of benefit compared unfavorably to Amgen’s recently...

Novo Nordisk officially launched an oral formulation of its GLP‑1 obesity drug Wegovy in the U.S., listing insured patient copays as low as $25 per month and a cash price of $149 for starting...

A U.S. Court of Appeals affirmed a lower court injunction preventing the National Institutes of Health from imposing a 15% cap on indirect cost reimbursements to universities and research...

Researchers at St. Jude developed CHANGE‑seq‑BE, an unbiased, sensitive method to profile genome‑wide off‑target activity of CRISPR base editors to support safety evaluation in therapeutic...

Illumina released Connected Multiomics, a cloud‑based software suite that integrates multiomic data types with AI‑driven analytics and workflow automation to support scalable, connected biological...

Insilico Medicine completed a large Hong Kong IPO and immediately turned proceeds into a multiyear R&D tie‑up with Servier focused on oncology. The company raised roughly $292–293 million in the...

Pfizer and Cartography Biosciences struck a multiyear collaboration giving Pfizer options to license tumor‑selective antigens discovered with Cartography’s Atlas and Summit platforms. Pfizer...

Sanofi expanded its engagement with AI‑native Earendil Labs, signing a follow‑on agreement worth $160 million in upfront and near‑term payments and a broader collaboration framework that could...

Singapore‑based Deep Intelligent Pharma (DIP) closed a $50 million Series D to scale an AI platform that automates clinical trial design and execution. The company says its system decomposes...

Arrowhead Pharmaceuticals reported interim signals from RNAi candidates in obesity and announced plans to advance at least one program, ARO‑INHBE, into Phase 2 testing after early cohorts showed...

Novo Nordisk launched an oral form of semaglutide branded as Wegovy and started U.S. distribution with pricing tiers intended to expand access: as low as $25 per month for insured patients under...

Zenas Biopharma reported positive topline results from its Phase 3 Indigo trial of obexelimab in immunoglobulin G4‑related disease (IgG4‑RD) but investors reacted sharply after comparing effect...

U.K. biotech Ikarovec partnered with gene‑delivery specialist VectorBuilder to evaluate AAV capsids engineered to enable intravitreal delivery of an ocular gene therapy for intermediate...